Cell Signaling Technology and Visiopharm Announce Partnership to Advance Spatial Biology Research

Streamlined multiplex immuno-profiling capabilities and AI-driven image analysis will be demonstrated during a poster presentation at AACR 2025.

Danvers, MA, USA — Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, and Visiopharm, a global leader in AI-driven precision pathology software, today announced a strategic partnership to advance spatial biology research. The collaboration enables more streamlined analysis of images generated using the SignalStar^® Multiplex IHC technology in Visiopharm’s Phenoplex software, helping researchers to more efficiently interrogate cellular interactions in the tumor microenvironment and streamline biomarker discovery and analysis.

“As multiplexed spatial biology assays become more flexible and robust, they must be paired with powerful, AI-driven image analysis solutions to truly uncover meaningful insights,” says Roberto (Roby) Polakiewicz, PhD, Chief Scientific Officer at CST. “We’re excited to partner with Visiopharm to provide researchers with a comprehensive toolbox of proven solutions so they can conduct advanced analyses of the tumor microenvironment with confidence.”

Through the partnership, CST and Visiopharm will deliver multiplexed biomarker staining, signal amplification, and data annotation and analysis capabilities, enabling spatial biology researchers to uncover actionable insights about disease progression and therapeutic response.

“At Visiopharm, we are committed to empowering researchers with AI-driven image analysis solutions that unlock the full potential of spatial biology,” said Regan Baird, PhD, Chief Research Solutions Officer at Visiopharm. “By combining CST’s cutting-edge multiplex IHC technology with our advanced Phenoplex software, we are enabling scientists to extract deeper, more precise insights into the tumor microenvironment. This partnership represents a significant step forward in accelerating biomarker discovery and advancing precision medicine.”

Visiopharm is a world leader in AI-based image analysis and workflow standardization, and CST offers best-in-class antibody technology for interrogating complex biological systems while maintaining their spatial context and tissue architecture. By combining the highly flexible antibody panels in the SignalStar Multiplex IHC assay with powerful AI-driven software from Visiopharm, biopharma researchers can confidently generate and analyze spatial data of the tumor microenvironment using a high-throughput method.

To demonstrate how CST and Visopharm’s capabilities in multiplex immuno-profiling can be leveraged together, the companies are presenting a poster at The American Association for Cancer Research (AACR) Annual Meeting 2025.

Poster:Spatial analysis of the DLBCL tumor microenvironment via the novel SignalStar^® multiplex immunohistochemistry assay
Authors: Jennifer Ziello, Shuling Zhang, Sarah Klein, Derek Papalegis, Lily Vu, Gabriella Spang, Arvin Ruiz and Giorgio Inghirami

To learn more, visit CST at AACR 2025 at booth #809 or stop by poster number 24 in the Spatial Proteomics and Transcriptomics 1 poster session.

About Cell Signaling Technology
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet. cellsignal.com 

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com. 

CST Media and Press 

Rebecca J. Reppucci, MBA 
Cell Signaling Technology, Inc. 
Senior Director, Global Marketing Communications 
Phone: +1-978-880-3334 
Email: marketingpr@cellsignal.com 

ID: 16755_03_2025